Highest-materiality recent filing
AIM ImmunoTech regains NYSE American listing compliance after equity deficiency resolved
Received NYSE American notice on June 12, 2026 that it resolved stockholders' equity deficiencies under Sections 1003(a)(i)-(iii).
AIM ImmunoTech prices $2.65 million registered direct offering and private placement
Company issued 2,554,119 registered shares and 771,503 unregistered shares at $0.5189 per share for gross proceeds of ~$2.65M.
AIM ImmunoTech amends bylaws: majority of votes cast standard for non-director proposals
Board approved Amendment to Bylaws effective June 9, 2026, changing voting standard for proposals other than director elections.
AIM ImmunoTech highlights Ampligen preclinical data for Ebola preparedness
Video discusses Ampligen as prophylactic/early-onset treatment for Bundibugyo Ebola strain with no approved therapies.
AIM ImmunoTech prices $2.4M registered direct offering of 7.5M shares and warrants
Offering of 7,519,351 shares at $0.325 per share; gross proceeds ~$2.4M before expenses.
AIM ImmunoTech increases stockholder equity to $2.1M, extends note maturity to June 2027
Stockholder equity rose to ~$2.1M as of March 31, 2026, from a deficit of ~$9.8M at Dec 31, 2025 (+$11.9M).
Named Patient Program shows PFS 12.6 months (+4 mo) and OS 19.7 months (+7.2 mo) vs historical controls.
AIM ImmunoTech closes warrant inducement, raises ~$3.6M gross
Holders exercised Existing Warrants for 7,451,920 shares at reduced price of $0.48 per share.
AIM ImmunoTech expects ~$4.2M gross from warrant inducement at $0.48/share; new warrants at $0.60
Existing warrants from May 2024, Sep 2024, Jul 2025 exercised at reduced exercise price of $0.48; gross proceeds ~$4.2M if fully exercised.
AIM ImmunoTech amends ATM agreement to remove $3M cap on share sales
Amendment No. 1 to Equity Distribution Agreement with Maxim Group removes the prior $3,000,000 limit on shares sold.
AIM ImmunoTech closes rights offering raising $1.8M; issues Series G Preferred and warrants
Gross proceeds of approximately $1.8 million from 1,842 units in rights offering.
Positive interim Phase 2 data for Ampligen+Imfinzi in metastatic pancreatic cancer
18 patients enrolled in DURIPANC Phase 2; combination well-tolerated with only two grade 3 immune-related AEs.
AIM ImmunoTech adjusts warrant exercise price to $1.439, increases warrant count to 5.56M each
Triggered by a 1-for-1,000 share stock dividend on January 13, 2026.
AIM ImmunoTech furnishes January 2026 corporate presentation
Presentation filed as Exhibit 99.1 on Form 8-K dated January 12, 2026.
All five director nominees elected with majority of votes cast; broker non-votes of 833,173 on each.
AIM ImmunoTech raises $2.5M via unsecured promissory note with Streeterville Capital
Net proceeds of $2,500,000 from $3,301,250 note after $781,250 OID and $20,000 transaction costs.
AIM ImmunoTech files amended and restated certificate of incorporation
Filed amended and restated Certificate of Incorporation as Exhibit 3.1(i) effective October 29, 2025.
AIM ImmunoTech furnishes investor presentation for Maxim Growth Summit 2025
Presentation furnished for Maxim Growth Summit 2025 taking place Oct 22-23, 2025 in New York.
AIM ImmunoTech closes $8.0M public offering of common stock and warrants
Gross proceeds of $8.0M from offering of 2M shares (or pre-funded warrants) and Class E/F warrants at $4.00 per share.
AIM ImmunoTech reports positive mid-year Phase 2 data for Ampligen+Imfinzi in pancreatic cancer
No grade ≥2 immune-related or systemic toxicities reported across 14 enrolled patients.
AIM ImmunoTech gets second NYSE American noncompliance notice for negative $3.9M equity
NYSE American warned AIM on June 17, 2025 for failing minimum stockholders' equity: negative $3.9M as of March 31, 2025.
AIM ImmunoTech completes 1-for-100 reverse split; regains NYSE American listing compliance
Reverse stock split at 1-for-100 ratio effective June 12, 2025; new CUSIP 00901B303.
AIM ImmunoTech shareholders approve reverse stock split up to 1-for-100
Special meeting held April 30, 2025; proposal passed with 23,041,332 for, 19,942,903 against.
AIM ImmunoTech receives NYSE American delisting notice for low stock price; plans appeal
Received notice on April 4, 2025 from NYSE American of suspension and delisting under Section 1003(f)(v) due to low selling price.
AIM ImmunoTech enters ATM offering agreement for up to $3M common stock
Entered Equity Distribution Agreement with Maxim Group LLC for at-the-market offering of up to $3M common stock.
NYSE American accepts AIM ImmunoTech's plan to regain listing compliance; deadline June 11, 2026
Plan accepted under Sections 1003(a)(ii) and 1003(a)(iii) of NYSE American Company Guide.
David Chemerow appointed as independent director, effective February 24, 2025.
AIM ImmunoTech delays S-1 offering until after filing 2024 Annual Report
Will not proceed with S-1 offering until after filing Form 10-K for fiscal year ended December 31, 2024.
Phase 1 safety data showed combination generally well-tolerated with no severe adverse events or dose-limiting toxicities.
Aim ImmunoTech plans combo study of Ampligen and FluMist for avian flu
Plans to file IND for trial combining Ampligen with AstraZeneca's FluMist to target avian influenza.
AIM ImmunoTech gets safety committee nod for Phase 2 of Ampligen + Imfinzi in pancreatic cancer
Safety committee approved Phase 2 based on Phase 1 data: no severe adverse events or dose-limiting toxicities.
AIM ImmunoTech officers Equels and Rodino voluntarily forego 2024 cash bonuses to fund Ampligen R&D
CEO Thomas K. Equels and Peter W. Rodino III notified the Compensation Committee they will forgo their 2024 cash bonuses.
AIM ImmunoTech annual meeting elects one dissident nominee, say-on-pay fails
Nancy K. Bryan, Thomas K. Equels, Ted D. Kellner (dissident), and William M. Mitchell elected directors.
AIM ImmunoTech receives NYSE American delisting notice for stockholders' equity deficit
Stockholders' deficit of $2.9M as of Sept 30, 2024; fails $4M and $6M equity thresholds.
AIM ImmunoTech adopts Cash Conservation Plan; independent directors paid entirely in stock
Independent directors will receive 100% of board compensation in shares, effective immediately; no cash compensation.
AIM ImmunoTech raises $1.26M via registered direct offering and warrant private placement
Issues 4,653,036 shares at $0.27 each; gross proceeds ~$1.26M before placement agent fees.
AIM ImmunoTech amends CEO/COO employment: CEO salary $650k plus $100k stock
CEO Equels: cash salary reduced to $650,000, plus $100,000 in restricted shares for one year ending Sept 11, 2025.
AIM ImmunoTech adopts amended bylaws following Delaware Supreme Court ruling
Company adopted Restated and Amended Bylaws on July 31, 2024.
Delaware Supreme Court rules on AIM Immunotech bylaw challenge; election unchanged
Delaware Supreme Court affirmed in part, reversed Court of Chancery post-trial decision in Kellner v. AIM Immunotech.
AIM ImmunoTech raises $2.0M in registered direct offering and warrant placement
Issues 5,640,958 shares at $0.363/share for gross proceeds of ~$2.0M to a single institutional investor.
AIM ImmunoTech raises $2.5M via private placement of 10% unsecured promissory note
Original principal $3,301,250; $781,250 OID and $20,000 legal fees deducted, net proceeds $2,500,000.
AIM ImmunoTech reports positive Phase 2 topline results for Ampligen in post-COVID fatigue
Primary endpoint (PROMIS Fatigue Score at week 13) not significant; Ampligen showed lower fatigue at multiple timepoints vs placebo.
AIM ImmunoTech furnishes supplemental data deck on pancreatic cancer Early Access Program
Deck titled 'Pancreatic Cancer Early Access Program Supplemental Data Q1 2024' furnished as Exhibit 99.1.
AIM ImmunoTech opens enrollment in Phase 1b/2 trial of Ampligen + Imfinzi for pancreatic cancer
Enrollment open at Erasmus MC for DURIPANC study combining Ampligen + AstraZeneca's Imfinzi; dosing expected soon.
AIM ImmunoTech shareholders reject advisory compensation vote; directors elected
Four director nominees elected: Appelrouth (6.95M for), Bryan (10.52M), Equels (10.29M), Mitchell (6.68M).
AIM Immunotech files 8-K with Q3 2023 update presentation; no specific data available in filing text
Filing includes a company presentation as Exhibit 99.1 titled Q3 2023 Update Conference Call and dated November 15, 2023.
AIM Immunotech presents ovarian cancer chemoimmunotherapy data at SITC 2023
Poster presented at SITC 38th Annual Meeting (Nov 1-5, 2023) by UPMC collaborators.
AIM ImmunoTech enters amended research agreement with Roswell Park for Ampligen® studies
Agreement covers three clinical trials: melanoma, prostate cancer, triple-negative breast cancer.
AIM ImmunoTech to present Ampligen oncology data at Roswell Park symposium
Chris McAleer, Ph.D., Scientific Officer, will present at the Marie Sklodowska-Curie Symposium on Cancer Research and Care at Roswell Park.
AIM ImmunoTech rejects stockholder Kellner's director nominations as invalid
Board determined notice from Ted D. Kellner nominating himself, Todd Deutsch, and Robert L. Chioini fails to comply with company bylaws.
On February 26, 2025, AIM ImmunoTech Inc. (the "Company") issued a press release announcing the appointment of David I. Chemerow to its Board of Directors (the "Board"), effective February 24, 2025
On March 30, 2023, AIM ImmunoTech Inc. (the “Company”) issued a press release announcing the appointment of Nancy Bryan to its Board of Directors (the “Board”), effective March 28, 2023
On March 1, 2022, the Company entered into a consulting agreement with Ellen Lintal, who will step down as the Company’s Chief Financial Officer on April 4, 2022.
On March 1, 2022, after review and approval by the Board of Directors, the Company entered into a consulting agreement with Foresite Advisors, LLC, a company wholly-owned by Robert Dickey IV, pursuant to which Mr. Dickey will serve as the Company’s new Chief Financial Officer effective April 4, 2022.
Max materiality 0.80 · Median 0.55 · Most common event other_material